LifeMD reported Q3 2025 consolidated revenue of $60.2 million, a 13% increase year-over-year, with telehealth revenue growing 18% to $47.3 million and telehealth adjusted EBITDA increasing 30% to $2.9 million. The company ended the quarter with $23.8 million in cash and no debt following the divestiture of its majority interest in WorkSimpli.
The company provided Q4 2025 revenue guidance of $45-$46 million and adjusted EBITDA guidance of $3-$4 million. For the full year 2025, revenue is expected to be between $192-$193 million, and adjusted EBITDA is projected to be between $13.5-$14.5 million.
The RexMD business returned to growth, adding approximately 10,000 net new subscribers, and the weight management offering has stabilized. LifeMD announced new pricing for Wegovy and Ozempic for self-pay patients, offering initial doses at $199 and higher doses at $349 per month, and anticipates offering oral GLP-1 therapies in 2026.
Strategic initiatives include the regulatory approval of a non-sterile 503A compounding pharmacy, significant progress in women's health and behavioral health offerings, and the upcoming launch of a unified LifeMD platform and marketplace. Insurance enablement, a key strategic priority, has demonstrated a 33% reduction in customer acquisition costs.

1 day ago

Transcript

LifeMD Reports Q3 2025 Financial Results and Provides 2025 Outlook

LFMD

Earnings

Guidance Update

Revenue Acceleration/Inflection

LifeMD reported Q3 2025 consolidated revenue of $60.2 million, a 13% increase year-over-year, with telehealth revenue up 18% to $47.3 million and telehealth adjusted EBITDA growing 30% to $2.9 million.
The company strengthened its balance sheet by divesting its majority interest in WorkSimpli, resulting in $23.8 million in cash and no debt at quarter-end.
RexMD returned to growth, adding approximately 10,000 net new subscribers, and the weight management offering has stabilized, with new pricing for branded GLP-1s (Wegovy/Ozempic) and anticipated oral Wegovy launch in early 2026 through collaborations with Novo Nordisk and Eli Lilly.
LifeMD secured regulatory approval for its non-sterile 503A compounding pharmacy and is investing in women's and behavioral health offerings, which are expected to become "nine-figure businesses".
For Q4 2025, the company expects revenue between $45 million and $46 million and adjusted EBITDA between $3 million and $4 million. Full-year 2025 guidance projects revenue of $192 million-$193 million and adjusted EBITDA of $13.5 million-$14.5 million.

1 day ago

Transcript

LFMD Announces Q3 2025 Results and Provides 2025 Guidance Update

LFMD

Earnings

Guidance Update

M&A

LifeMD provided 2025 revenue guidance of $192 million to $193 million, reflecting a 24% to 25% increase over FY 2024, and Telehealth Adjusted EBITDA guidance of $13.5 million to $14.5 million for FY 2025, a significant increase from $4.1 million in FY 2024.
For Q3 2025, the company reported Telehealth Adjusted EBITDA of $2.87 million, contributing to $10.49 million for the nine months ended September 30, 2025.
LifeMD completed the divestiture of its majority ownership interest in the non-core WorkSimpli asset, establishing itself as a pure-play telehealth and pharmacy services company.
As of September 30, 2025, the company served 310,000 active patients and had conducted 1.3 million virtual consults. The company also noted 85%+ consolidated gross margins.

1 day ago

Presentation

LifeMD Reports Third Quarter 2025 Results and Provides Guidance

LFMD

Earnings

Guidance Update

Revenue Acceleration/Inflection

LifeMD reported a 13% year-over-year increase in total revenue to $60.2 million and a 20% rise in adjusted EBITDA to $5.1 million for Q3 2025.
Telehealth revenue specifically grew 18% to $47.3 million, with telehealth adjusted EBITDA increasing 30% to $2.9 million. The number of active telehealth subscribers also increased 14% to approximately 310,000 at quarter-end.
The company paid off all outstanding debt during the quarter and, subsequent to quarter-end, fully divested its majority stake in WorkSimpli, positioning LifeMD as a pure-play telehealth and pharmacy platform.
LifeMD provided Q4 2025 revenue guidance of $45 million to $46 million and adjusted EBITDA guidance of $3 million to $4 million for its stand-alone telehealth business. For the full year 2025, the company expects revenue between $192 million and $193 million (a 24% increase versus 2024) and adjusted EBITDA between $13.5 million and $14.5 million (a 254% increase versus 2024).

1 day ago

8-K

LifeMD Reschedules Q3 2025 Earnings Release Due to Accounting Corrections

LFMD

Earnings

Financial Restatement

Accounting Changes

LifeMD, Inc. has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025, from the original date of November 5, 2025.
The rescheduling is due to identified corrections related to the recognition of revenue with offsetting related balance sheet accounts for the twelve months ended December 31, 2023, December 31, 2024, and the six months ended June 30, 2025.
The cumulative impact of these changes will be approximately $4.6 million, or about 1.4% of cumulative revenue reported for the twelve months ended December 31, 2024, and six months ended June 30, 2025.
These required adjustments will not materially impact how reported revenue results compared to guidance for the reporting periods during this timeframe, nor will they impact the Company's cash flow or cash position.
LifeMD expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025.

Nov 5, 2025, 10:27 PM

8-K

LifeMD Reschedules Q3 2025 Earnings Due to Accounting Corrections

LFMD

Financial Restatement

Accounting Changes

Delisting/Listing Issues

LifeMD, Inc. has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025.
The rescheduling is due to identified corrections related to revenue recognition and offsetting balance sheet accounts for the twelve months ended December 31, 2023, December 31, 2024, and the six months ended June 30, 2025.
The cumulative impact of these changes is approximately $4.6 million, representing about 1.4% of cumulative revenue reported for the twelve months ended December 31, 2024, and six months ended June 30, 2025.
LifeMD expects these adjustments will not materially impact reported revenue results compared to guidance for the affected periods, nor will they impact the company's cash flow or cash position. The company also expects to file a Form 12b-25 for a late filing of its Form 10-Q for the period ended September 30, 2025.

Nov 5, 2025, 10:15 PM

Press Release

LifeMD Divests Majority Interest in WorkSimpli Software

LFMD

M&A

New Projects/Investments

LifeMD, Inc. divested its majority ownership interest in WorkSimpli Software LLC on November 4, 2025.
The transaction valued WorkSimpli at an enterprise value of approximately $65 million.
LifeMD received approximately $22 million in cash at closing and is eligible to receive up to an additional $28 million in cash based on WorkSimpli achieving defined growth and operational targets over the next three years.
This divestiture positions LifeMD as a pure-play virtual care and pharmacy platform, allowing it to concentrate resources on expanding its virtual care and pharmacy offerings.
LifeMD previously held 73.3% ownership of WorkSimpli's outstanding units immediately prior to the transaction, having made an initial investment of $250,000 in June 2018 for a 51% equity interest, with a total investment of approximately $1.25 million.

Nov 4, 2025, 7:48 PM

8-K

LifeMD Faces Securities Class Action Lawsuit

LFMD

Legal Proceedings

Guidance Update

Profit Warning

Faruqi & Faruqi, LLP is investigating potential claims against LifeMD (NASDAQ: LFMD) following a federal securities class action filing.
The lawsuit alleges that LifeMD executives made false or misleading statements, including overstating the company's competitive position and being reckless in raising 2025 guidance without properly accounting for rising customer acquisition costs.
On August 5, 2025, LifeMD announced revised 2025 total revenue guidance of $250 million to $255 million, a decrease from the previous $268 million to $275 million.
Following this news, LifeMD's stock plummeted 44.8% on August 6, 2025.
The deadline for investors who suffered losses exceeding $75,000 between May 7, 2025, and August 5, 2025, to seek the role of lead plaintiff was October 27, 2025.

Oct 29, 2025, 2:25 PM

Press Release

LifeMD Under Investigation Following Revised Guidance

LFMD

Legal Proceedings

Guidance Update

Demand Weakening

Faruqi & Faruqi, LLP is investigating LifeMD, Inc., and a federal securities class action has been filed against the company, alleging false or misleading statements by executives.
The complaint claims LifeMD executives overstated the company's competitive position and were reckless in raising 2025 guidance without properly accounting for rising customer acquisition costs.
On August 5, 2025, LifeMD announced revised guidance, lowering expected total revenue to $250 to $255 million from the previous $268 to $275 million.
Following this announcement, LifeMD's stock plummeted 44.8% on August 6, 2025.
Investors who suffered losses between May 7, 2025, and August 5, 2025, have until October 27, 2025, to seek the role of lead plaintiff.

Oct 26, 2025, 1:03 PM

Press Release

LifeMD Faces Federal Securities Fraud Class Action Lawsuit

LFMD

Legal Proceedings

Guidance Update

Demand Weakening

A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging the telehealth company provided investors with a misleading picture of its financial health and growth prospects.
The lawsuit, captioned Johnston v. LifeMD, Inc., focuses on the period between May 7 and August 5, 2025, alleging LifeMD made false and misleading statements, particularly on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance.
The complaint claims the company's optimistic outlook was false as it failed to account for crucial business challenges, including rising customer acquisition costs in its RexMD segment and a higher-than-anticipated refund rate in its weight management business.
The alleged deception unraveled on August 5, 2025, when LifeMD announced Q2 results, missing revenue and EPS estimates and subsequently slashing its full-year guidance, leading to a 44% stock price plummet the following day.
The lead plaintiff deadline for investors who suffered substantial losses is October 27, 2025.

Oct 25, 2025, 6:49 PM

Press Release

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for LFMD.

No recent filings or transcripts found for LFMD.